Paper816248
Comparative in vitro evaluation of the effects of ticarcillin and carbenicillin upon Psuedomonas aeruginosa.
Kalkani E and 1 other. Antimicrob Agents Chemother, 1976. Cited by 9 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Comparative in vitro evaluation of the effects of ticarcillin and carbenicillin upon Psuedomonas aeruginosa. Papers, record 816248. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/816248
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparative in vitro evaluation of the effects of ticarcillin and carbenicillin upon Psuedomonas aeruginosa.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carbenicillin | Major topic |
| Penicillins | Major topic |
| Pseudomonas aeruginosa | Major topic |
| Ticarcillin | Major topic |
| Penicillin Resistance |
Source PubMed
References4
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 4,958,434 | Typing of Pseudomonas pyocyanea by pyocine production. | J Pathol Bacteriol | 1966 | https://conductscience.org/library/papers/4958434 | PubMed |
| 2 | 4,937,796 | Carbenicillin therapy for pseudomonas infections. | JAMA | 1971 | https://conductscience.org/library/papers/4937796 | PubMed |
| 3 | 4,902,581 | Carbenicillin: clinical and laboratory experience with a parenterally administered penicillin for treatment of Pseudomonas infections. | Ann Intern Med | 1969 | https://conductscience.org/library/papers/4902581 | PubMed |
| 4 | 806,263 | BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1975 | https://conductscience.org/library/papers/806263 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7,002,527 | Ticarcillin: a review of its pharmacological properties and therapeutic efficacy. | Drugs | 1980 | https://conductscience.org/library/papers/7002527 | PubMed |
| 417,671 | Comparison of ticarcillin and carbenicillin activity against random and select populations Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1978 | https://conductscience.org/library/papers/417671 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/816248
GET https://conductscience.org/api/papers/v1/816248/authors